In Week of Mar 28, 2026, Torrent Pharmaceuticals Ltd (Pharma - Formulators) is outperforming Nifty 500 with +23.4% relative strength. Fundamentals: Average. On a 12-week streak.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Based on Q3 FY26 (Quarter ended December 31, 2025) earnings • Updated Feb 22, 2026
What: ₹400-450 cr cost synergies over 2-3 years with 20% in FY26
“Management stated: "So broadly I would say that our synergy number is looking like 400 450 crores over the next 2 to 3 years. Uh you know maybe 20% of that could be in the first year up to 80% of that could be in the second year and the rest in the third year."”
What: 14% growth in India business driven by chronic therapy outperformance
“Management stated: "We are seeing continued volume outperformance over the IPM in chronic and subchronic therapies led by cardiac, gastro and diabetes segments."”
What: 27% growth in Curatio business driven by ad spends and field force expansion
“Management stated: "The curatio business grew at 27% in Q3 and also 27% in YTD 9 months for the year driven by strong demand generation on account of OTC ad spends and field force expansion."”
Earnings deceleration risks from management commentary
Trigger: Ongoing supplier disruption
Management view: Management stated: "As highlighted last quarter, growth continues to be impacted due to disruption at a third party supplier."
Monitor: US revenue growth
Trigger: Integration process challenges
Management view: Management stated: "What we do expect is a bit of a course correction in this current Q4 because in any change of control situation there are changes of business practices and uh I mean you have to kind of integrate processes..."
Monitor: US business performance
Key quotes from recent conference calls
“this quarter we continue to see healthy performance in our branded markets which accounted for roughly 75% of the overall revenues this quarter. Our two largest branded markets, India and Brazil, each continue to deliver healthy double-digit growth. India business grew at 14% and Brazil grew at 27%. — Management”
“Operating AITA at 1088 crores grew by 19%. And operating aida margin stands at 32.9%. — Management”
“So broadly I would say that our synergy number is looking like 400 450 crores over the next 2 to 3 years. Uh you know maybe 20% of that could be in the first year up to 80% of that could be in the second year and the rest in the third year. — Management”
“So combining a muted pricing increase, some volume increase and new products I think in the range of 10 to 15% is reasonable to expect. — Management”
Forward-looking targets from management for Next 2-4 quarters
Revenue Growth Target
10%
Key Milestones
• ₹400-450 cr synergies realization
• US business reaching $200 million annual revenue
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +18% | +11% | Accelerating |
| PAT (Net Profit) | +26% | +35% | Stable |
| OPM | 33.0% | 0 bps | Expanding |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Feb 22, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Torrent Pharmaceuticals Ltd's latest quarterly results (Dec 2025) show
Torrent Pharmaceuticals Ltd's profit is growing with an stable trend.
Torrent Pharmaceuticals Ltd's revenue growth trend is accelerating.
Torrent Pharmaceuticals Ltd's operating margin is expanding.
Torrent Pharmaceuticals Ltd's long-term compounding rates
Torrent Pharmaceuticals Ltd's earnings growth is stable with positive momentum on a sequential basis.
Torrent Pharmaceuticals Ltd's trailing twelve month (TTM) performance
Torrent Pharmaceuticals Ltd appears undervalued based on our fair value analysis.
Torrent Pharmaceuticals Ltd's current PE ratio is 62.6x.
Torrent Pharmaceuticals Ltd's current PE is 62.6x.
Torrent Pharmaceuticals Ltd's price-to-book ratio is 17.1x.
Torrent Pharmaceuticals Ltd is rated Average with a fundamental score of 57.96/100. This score is calculated from objective financial metrics
Torrent Pharmaceuticals Ltd has a debt-to-equity ratio of N/A.
Torrent Pharmaceuticals Ltd's return ratios over recent years
Torrent Pharmaceuticals Ltd's operating cash flow is positive (FY2025).
Torrent Pharmaceuticals Ltd's current dividend yield is 0.75%.
Torrent Pharmaceuticals Ltd's shareholding pattern (Dec 2025)
Torrent Pharmaceuticals Ltd's promoter holding has remained stable recently.
Torrent Pharmaceuticals Ltd has been outperforming Nifty 500 for 12 consecutive weeks, indicating strong sustained outperformance.
Torrent Pharmaceuticals Ltd is an established outperformer with 12 weeks of consecutive Nifty 500 outperformance.
Torrent Pharmaceuticals Ltd has 3 key growth catalysts identified from recent earnings analysis
Torrent Pharmaceuticals Ltd has 2 key risks worth monitoring
In Q3 FY26 (Quarter ended December 31, 2025), Torrent Pharmaceuticals Ltd's management highlighted
Torrent Pharmaceuticals Ltd's management has provided the following forward guidance for Next 2-4 quarters
Based on quantitative research signals, here is why Torrent Pharmaceuticals Ltd may be worth studying
Torrent Pharmaceuticals Ltd investment thesis summary:
Torrent Pharmaceuticals Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
